Calmark signs distributor agreement with Bergman Diagnostika in Norway
Calmark Sweden AB (publ) has entered an exclusive distributor agreement with the company Bergman Diagnostika AS, part of the Triolab Group, regarding marketing and sales of the Calmark POC system on the Norwegian market. The agreement provides Calmark with an additional well-established partner on the important domestic market.
Bergman Diagnostika has more than 20 years of experience in distributing products to the Norwegian health care and laboratories. The company operates in the customer segments that are important to Calmark, and especially sells products in clinical diagnostics and point-of-care for hospitals, laboratories and primary care.
"Bergman Diagnostika very well matches the distributor profile that we are looking for; they have complementary products in its portfolio, they stay close to the customer and provide the best possible support and service, and they have established logistics in place for the whole market, which is important to be able to become a good distributor for our products," says Magdalena Tharaldsen, Director International Business Development of Calmark.
"We are delighted that we have been able to conclude a further agreement in the Nordic countries," says Anna Söderlund, CEO of Calmark. "We are looking forward to the cooperation with such a well-established distributor in Norway."
Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
For more information about Calmark Sweden AB, please contact:
Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se
www.calmark.se
Calmark Sweden AB is a medical technology company developing a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark develops a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.
